Tag: pharmacotherapy
-
Prozac for Children: No Benefit Over Placebo, Experts Say
Overview: What the latest findings mean for young people Recent analyses and expert interpretations suggest that Prozac (fluoxetine) does not demonstrate clinically meaningful benefits for treating depression in children and adolescents beyond a placebo effect. This conclusion is prompting fresh conversations about how and when antidepressants should be prescribed to younger patients and which guidelines…
-
Weill Cornell and UM Miller Researchers Secure $4 Million to Study Economics of Substance Use Disorder Treatments
Five-Year, $4 Million NIDA Grant Aims to Decode the Economics of SUD Treatments A collaboration between Weill Cornell Medicine and the University of Miami’s Miller School of Medicine has secured a five-year, $4 million grant from the National Institute on Drug Abuse (NIDA) to advance health economics research in substance use disorder (SUD) treatment. The…
-
Remdesivir Linked to Lower Long-Term Mortality After COVID-19 Hospitalization: Real-World Evidence
Overview New real-world data from three health systems in Colorado and Utah suggest that receiving remdesivir (RDV) during a COVID-19–related hospitalization is associated with lower all-cause mortality after discharge. The study analyzed patients who survived their initial hospitalization and followed them for up to 29 months to assess long-term outcomes, including mortality, readmission to hospital,…
-
Weight-loss injections: Real people, real journeys with Ozempic, Mounjaro and friends
Rising hope, rising costs: weight-loss injections in real lives Across Europe and beyond, prescription weight-loss medications have moved from clinical trials to everyday use. The stories of several adults—from small-business owners to healthcare workers and parents—highlight a common thread: these drugs can dramatically alter health, mindset, and daily routines, but they come with costs, side…
-
Sex- and gender-responsive management of anxiety disorders: future pathways for research, education, policy and practice
Introduction: why sex and gender matter in anxiety disorders Anxiety disorders are the most common mental health condition in Australia, affecting a substantial portion of the population annually. While prevalence is higher in women and gender minorities, the patient journey—from symptom onset to diagnosis and treatment—varies across sex and gender lines. This article outlines how…
-
Sex- and gender-responsive management of anxiety disorders: pathways for Australia
Introduction: The need for sex- and gender-responsive anxiety care Anxiety disorders are the most common class of mental health conditions in Australia, affecting roughly 17% of people annually. This article examines how sex (biological factors) and gender (sociocultural influences) shape both the risk and the management of anxiety disorders, and it outlines future pathways for…